OneSource Speci.
OneSource Speci. Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Revenue affected short-term due to regulatory delays, especially in Canada, but strong recovery expected from FY '27 onwards. FY '26 is a transitory year with focus on building operating capacity and scale readiness.
From OneSource Speci.'s Q3 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Revenue affected short-term due to regulatory delays, especially in Canada, but strong recovery expected from FY '27 onwards.
- FY '28 guidance reiterated with confidence to become a ₹400 crore revenue company organically.
- Customer orders strengthening with an expanding product pipeline, including drug-device combinations and biologics.
- Capacity expansion capex of over ₹700 crore progressing well; significant additional capacities expected by H2 FY '27.
- Customer forecasts are being revised upward consistently, indicating growing demand.
- Sequential quarter-on-quarter improvement anticipated starting FY '27 as approvals materialize.
- Biologics CDMO business showing strong growth with RFPs almost 4x of previous levels and new major biosimilar customers onboarded.
2 more points from OneSource Speci.'s call on revenue
Every concall, every company
Profitability & Margins
See what OneSource Speci. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site expansion, particularly in the DDC (Drug Device Combination) business.
- By end of FY27, installed new capacities worth around $200 million are expected, with incremental capacity enhancements happening throughout the year.
- Investments include building microbial capacity for biologics CDMO, considered unique and competitive.
- Capex plans also cover expansion in lyophilization and new capabilities at the general injectables site in Bangalore.
- Around three-quarters of the planned $100 million capex for the flagship site have already been committed.
2 more points from OneSource Speci.'s call on capex
Every concall, every company
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what OneSource Speci. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- OneSource has strong visibility from customers, including long-term commitments extending beyond three years.
- They prioritize commercial sales over MSAs (Manufacturing Service Agreements) to optimize capacity utilization and economics.
- Customer orders continue to strengthen despite near-term approval delays.
- Customer forecasts are being revised upwards consistently, reflecting confidence in future demand.
- The company has been renegotiating take-or-pay contracts to secure more structured, longer-term relationships.
- Inventory build-up for significant upcoming semaglutide launches is customer-backed with advances or firm purchase orders.
2 more points from OneSource Speci.'s call on order book
Every concall, every company
OneSource Speci. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹428 Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What OneSource Specialty Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Fermenta Biotech Ltd (Q3 FY26)
Q3FY26 Revenue: INR 140.5 crore (down 11% YoY, up 4% QoQ) . Key concall takeaways from Fermenta Biotech Ltd's Q3 FY26 earnings call — and how it ranks against…
- Amrutanjan Health Care Ltd (Q3 FY26)
141.03 Cr, up 14.90% YoY (Q3 FY25: Rs. Key concall takeaways from Amrutanjan Health Care Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Sanjivani Paranteral Ltd (Q3 FY26)
Pune infusion plant ramping up capacity from ~23% to 40-50% utilization in FY '27. Key concall takeaways from Sanjivani Paranteral Ltd's Q3 FY26 earnings call…
Arthneeti Pro · Annual
OneSource Speci. and 1,500+ more calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were OneSource Speci. Q3 FY26 results?
Revenue affected short-term due to regulatory delays, especially in Canada, but strong recovery expected from FY '27 onwards. FY '26 is a transitory year with focus on building operating capacity and scale readiness.
What is OneSource Speci. share price analysis?
OneSource Speci. currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹17,602 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Speci. planning capital expenditure?
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site expansion, particularly in the DDC (Drug Device Combination) business.
Keep OneSource Speci. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.